Status:
COMPLETED
The Effect of Tranexamic Acid in Total Blood Loss During Proximal Femoral Nailing
Lead Sponsor:
Haseki Training and Research Hospital
Conditions:
Hip Fractures
Intertrochanteric Fractures
Eligibility:
All Genders
65+ years
Brief Summary
Blood loss is an important issue following intertrochanteric femoral fracture and may lead to requiring blood transfusions and transfusion complications. Tranexamic acid is a commonly used drug to dec...
Detailed Description
Introduction Intertrochanteric femur fractures may cause an average of 800-1500 cc of bleeding. Hip fractures, which reduce the intravascular volume so much, can cause serious metabolic problems in th...
Eligibility Criteria
Inclusion
- Patients aged ≥ 65 years with intertrochanteric fracture
- Treated with closed reduction and proximal femoral nailing
- Injury time ≤ 8 h.
Exclusion
- Having undergone previous surgery on the same hip,
- Fracture requiring open reduction,
- Having any contraindications for the use of tranexamic acid
- Patients with recent or ongoing thromboembolic events
- Patients who were recently taking or who were taking anticoagulation therapy and platelet aggregation inhibitors;
- Patients with disseminated intravascular coagulation or patients had hepatic or renal diseases with impairment of coagulation function.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 10 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05359172
Start Date
April 1 2021
End Date
July 10 2022
Last Update
October 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haseki TRH
Istanbul, Sultangazi, Turkey (Türkiye), 34000